Loading

PTSD

  • by Danielle Keane, NORML Associate June 24, 2016

    ballot_box_leafThis has been an exceptionally busy week at the state and federal level for marijuana law reform. Keep reading to get the latest news and to find out how you can #TakeAction.

    Federal:

    A bipartisan coalition of House and Senate lawmakers have proposed legislation, the Medical Marijuana Research Act of 2016, to expedite clinical investigations into the safety and efficacy of cannabis. Passage of the measures — House Bill 5549 and Senate Bill 3077 — would expedite federal reviews of clinical protocols involving cannabis, provide greater access to scientists who wish to study the drug, and mandate an FDA review of the relevant science. #TakeAction

    State:

    Arkansas: Representatives of the group Arkansas for Compassionate Care turned in over 100,000 signatures from registered voters this week in hopes of qualifying the 2016 Arkansas Medical Cannabis Act for the November ballot. The proposed initiative establishes a statewide program for the licensed production, analytic testing, and distribution of medicinal cannabis. Under the program, patients diagnosed by a physician with one of over 50 qualifying conditions – including ADHD, intractable pain, migraine, or post-traumatic stress – may obtain cannabis from one of up to 38 licensed non-profit care centers. Qualified patients who do not have a center operating in their vicinity will be permitted to cultivate their own medicine at home.

    In 2012, 51 percent of voters narrowly rejected a similar statewide initiative, known as Measure 5. However, recent polling shows that support has increased dramatically since then, with 84 percent of registered Arkansas voters agreeing that “adults should be legally allowed to use marijuana for medical purposes.”

    For more information on the campaign, please visit Arkansans for Compassionate Care.

    California: Both the American Civil Liberties Union of California and the California Democratic Party have publicly endorsed the Adult Use of Marijuana Act (AUMA). The initiative, which is expected to appear on the November ballot, permits adults to legally grow (up to six plants) and possess personal use quantities of cannabis (up to one ounce of flower and/or up to eight grams of concentrate) while also licensing commercial cannabis production and retail sales. The measure prohibits localities from taking actions to infringe upon adults’ ability to possession and cultivate cannabis for non-commercial purposes.

    oil_bottlesDelaware: House lawmakers have overwhelmingly approved legislation, SB 181, to permit designated caregivers to possess and administer non-smoked medical marijuana formulations (e.g. oils/extracts) to qualifying patients “in a school bus and on the grounds or property of the preschool, or primary or secondary school in which a minor qualifying patient is enrolled.” Senate lawmakers previously approved the bill on June 9th.

    Gov. Jack Markell, D-Delaware, is expected to sign the legislation into law. The measure will take effect upon the Governor’s signature. To date, two other states — Colorado and New Jersey — impose similar legislation.

    Florida: Elected officials of yet another Florida county have voted to provide local law enforcement with the option to cite rather than arrest minor marijuana possession offenders. Osceola County commissioners passed the ordinance on Tuesday. The new ordinance is similar to those recently passed in Orlando, Tampa, Volusia County, Palm Beach County, Broward County, West Palm Beach, Key West, Hallandale, Miami Beach and Miami-Dade county.

    New Jersey: Legislation to add PTSD to the list of qualifying conditions eligible for medical marijuana is moving forward through state legislature.

    Members of the Assembly approved the legislation in a 56 to 13 vote on June 16th. On the same day, members of the Senate Health, Human Services and Senior Citizens Committee approved an identical measure, Senate Bill 2345, in a 6 to 3 vote. Thirteen states already allow PTSD patients to access medical marijuana including Delaware, Maryland, and Pennsylvania.
    The measure now awaits a vote by the full Senate. #TakeAction

    New York: Legislation has been approved to facilitate the processing and sale of hemp and locally produced hemp products. The measures, A 9310 and S 6960, expand upon New York’s existing hemp research program to permit for the sale, distribution, transportation and processing of industrial hemp and products derived from such hemp. Under existing law, licensed farmers are only permitted to engage in the cultivation of hemp for research purposes as part of an academic program.

    Both chambers have approved the legislation so now it awaits a signature from Governor Andrew Cuomo.#TakeAction

    Rhode Island: House and Senate lawmakers approved House Bill 7142, legislation to permit post-traumatic stress patients to be eligible for medical cannabis treatment and to accelerate access to those patients in hospice care. Members of both chambers overwhelmingly approved the measure. It now heads to the desk of Democratic Governor Gina Raimondo.#TakeAction

    House and Senate lawmakers also approved legislation to create the “Hemp Growth Act “. This measure will classify hemp as an agricultural product that may be legally produced, possessed, and commercially distributed. The Department of Business Regulation will be responsible for establishing rules and regulations for the licensing and regulation of hemp growers and processors. The Department is also authorized to certify any higher educational institution in Rhode Island to grow or handle or assist in growing or handling industrial hemp for the purpose of agricultural or academic research. The legislation now awaits action from Governor Gina Raimondo. If signed, the law will take effect January 1, 2017.#TakeAction

  • by Paul Armentano, NORML Deputy Director May 23, 2015

    US CapitolThe majority of the US Senate Appropriations Committee on Thursday cast votes in favor of expanding medical cannabis access to United States veterans. The committee vote marks the first time that a majority of any body of the US Senate has ever decided in favor of increased cannabis access.

    Committee members voted 18 to 12 in favor of The Veterans Equal Access Amendment, sponsored by Republican Senator Steve Daines of Montana and Democratic Senator Jeff Merkley of Oregon. It was added in committee to a must-pass military construction and veterans affairs spending bill (the Military Construction, Veterans Affairs, and Related Agencies Appropriations Act). The bill is “certain” to pass on the Senate floor, according to a Drug Policy Alliance press release.

    Weeks ago, House members narrowly killed a similar amendment in the House version of the Appropriations Act by a floor vote of 210 to 213. Once the Senate version of the act is passed by the Senate floor, House and Senate leaders will need to reconcile the two versions.

    The Daines/Merkley amendment permits physicians affiliated with the US Department of Veterans Affairs (VA) to recommend cannabis therapy to veterans in states that allow for its therapeutic use. Under current federal law, VA doctors are not permitted to fill out written documentation forms authorizing their patients to participate in state-sanctioned medical cannabis programs.

    Stand-alone legislation (HR 667) to permit VA physicians to recommend cannabis therapy is pending in the US House of Representatives, Committee on Veterans Affairs: Health Subcommittee. A similar provision is also included in Senate Bill 683/HR 1538, The Compassionate Access, Research Expansion, and Respect States (CARERS) Act.

    NORML coordinated its 2015 legislative ‘fly-in’ and lobby day in Washington, DC this past week, where many attendees visited with US Senators and urged them to vote for the Daines/Merkley amendment, among other pending reform legislation. Archived presentations from the conference are online here.

    To learn and/or to contact your elected officials in regard to other pending marijuana law reform legislation, please visit NORML’s ‘Take Action Center’ here.

  • by Paul Armentano, NORML Deputy Director June 18, 2014

    The administration of oral THC mitigates symptoms of post-traumatic stress syndrome (PTSD), according to clinical trial data published online ahead of print in the journal Clinical Drug Investigation.

    Investigators at the Hebrew University Medical Center in Jerusalem assessed the safety and efficacy of oral THC as an adjunct treatment in ten subjects with chronic PTSD.

    Researchers reported, “The intervention caused a statistically significant improvement in global symptom severity, sleep quality, frequency of nightmares, and PTSD hyperarousal symptoms.”

    They concluded, “Orally absorbable delta-9-THC was safe and well tolerated by patients with chronic PTSD.”

    Separate clinical trial data has previously reported that the administration of nabilone, a synthetic endocannabinoid agonist, can reduce the severity and frequency of nightmares in patients with PTSD.

    In 2013, researchers at the New York University School of Medicine published findings indicating that PTSD subjects experience a decrease in their natural production of anandamide, an endogenous cannabinoid neurotransmitter. They hypothesized that an increase in the body’s production of cannabinoids would likely restore subjects’ natural brain chemistry and psychological balance. “[Our] findings substantiate, at least in part, emerging evidence that … plant-derived cannabinoids such as marijuana may possess some benefits in individuals with PTSD by helping relieve haunting nightmares and other symptoms of PTSD,” they concluded.

    Full text of the study, “Preliminary, open-label, pilot study of add-on oral delta-9-tetrahydrocannabinol in chronic post-traumatic stress disorder,” will appear in Clinical Drug Investigation.

  • by Paul Armentano, NORML Deputy Director March 18, 2014

    Michigan physicians may now authorize cannabis for the treatment of post traumatic stress.

    Members of the Medical Marihuana Review Panel voted 6 to 2 to expand the state’s list of qualifying conditions to include PTSD. The Director of the Michigan Department of Licensing and Regulatory Affairs has signed off on the recommendation.

    This is the first time that regulators have expanded the state’s list of qualifying conditions since voters initially legalized the physician authorized use of cannabis in 2008.

    Six other states — Connecticut, Delaware, Maine, New Mexico, Nevada, and Oregon — explicitly allow for the use of cannabis to treat symptoms of post-traumatic stress. Nevada regulators expanded their law to include PTSD earlier this year. Oregon and Maine lawmakers amended their medical cannabis laws last year to include post-traumatic stress.

    California physicians may recommend medical cannabis at their discretion.

    Clinical trial data published in the May issue of the journal Molecular Psychiatry theorized that cannabinoid-based therapies would likely comprise the “next generation of evidence-based treatments for PTSD (post-traumatic stress disorder).”

    Post-traumatic stress syndrome is an anxiety disorder that is estimated to impact some eight million Americans annually. To date, there are no pharmaceutical treatments specifically designed or approved to target symptoms of PTSD.

    Last week, federal officials at the Public Health Service approved the use of cannabis in a privately funded pilot trial at the University of Arizona College of Medicine to assess its potential risks and benefits in war veterans suffering from PTSD, including the plant’s potential impact on subjects’ anxiety, suicidality, and depression. Although the study was initially approved by the FDA in 2011, neither PHS nor the US National Institute on Drug Abuse (NIDA) signed off on the protocol until this month. Both agencies, as well as the US DEA, must approve any clinical trial involving cannabis.

  • by Paul Armentano, NORML Deputy Director June 27, 2013

    Patients diagnosed with post-traumatic stress, Crohn’s disease, and other debilitating disorders will now be eligible for cannabis therapy, under legislation approved yesterday absent the Governor’s signature.

    The new law expands the list of qualifying conditions for which a Maine physician may legally recommend cannabis to include “post-traumatic stress disorder,” “inflammatory bowel disease” (such as Crohn’s and/or ulcerative colitis), and “dyskinetic and spastic movement disorders and other diseases causing severe and persistent muscle spasms” (such as Parkinson’s disease and/or Huntington’s disease). It is the second time that Maine legislators have acted to expand the pool of patients who may have access to medicinal cannabis.

    Under state law, qualified patients in Maine may either cultivate their own cannabis or obtain it from one of eight state-licensed dispensaries.

    Four states — Connecticut, Delaware, New Mexico, and Oregon — specifically allow for the use of cannabis to treat symptoms of post-traumatic stress. Clinical trial data published in the May issue of the journal Molecular Psychiatry theorized that cannabinoid-based therapies would likely comprise the “next generation of evidence-based treatments for PTSD (post-traumatic stress disorder).”

    Survey data published in 2011 in the European Journal of Gastroenterology and Hepatology reports the use of cannabis therapy is common among patients with inflammatory bowel disorders. Most recently, researchers at the Meir Medical Center, Department of Gastroenterology and Hepatology in Israel reported that inhaling cannabis reduces symptoms of Crohn’s disease compared to placebo in patients non-responsive to traditional therapies. Investigators concluded, “Our data show that 8-weeks treatment with THC-rich cannabis, but not placebo, was associated with a significant decrease of 100 points in CDAI (Crohn’s Disease and activity index) scores.” (The CDIA is a research tool used to quantify the symptoms of Crohn’s disease patients.) Five of the eleven patients in the study group also reported achieving disease remission (defined as a reduction in patient CDAI score by more than 150 points).

Page 1 of 3123